Dementia: Scientists Find Specific Brain Regions Damaged by High Blood Pressure

Translate to Spanish or other 102 languages!

More than 55 million people globallyTrusted Source have dementia — an umbrella term for a number of diseases causing memory loss and cognitive declineTrusted Source. Image for illustration purposes
More than 55 million people globallyTrusted Source have dementia — an umbrella term for a number of diseases causing memory loss and cognitive declineTrusted Source. Image for illustration purposes

Medical News Today

- Advertisement -
  • High blood pressure is a known risk factor for developing dementia. 
  • Researchers recently identified the specific areas of the brain that may be damaged by high blood pressure and are linked to the development of dementia. 
  • Further studies may help researchers identify patients at high risk of cognitive impairment. 

More than 55 million people globallyTrusted Source have dementia — an umbrella term for a number of diseases causing memory loss and cognitive declineTrusted Source.

Follow the link below to Medical News Today to read the full Story:

https://www.medicalnewstoday.com/articles/dementia-scientists-find-specific-brain-regions-damaged-by-high-blood-pressure

- Advertisement -

Information Source: https://www.medicalnewstoday.com

- Advertisement -
- Advertisement -

- Advertisement -

More Articles

How Dogs Benefit Mind and Soul

"Dogs are wonderful greeters. They're waiting for you to come home, and they're always happy to see you. In turn, this increases our feel-good hormones, like dopamine and serotonin,” explained Chivonna Childs, PhD.

Data Reveals US Illicit Fentanyl Use is Double That of Clinical Care

The largest study to date that quantifies and compares medical and illegal use of fentanyl in the United States suggests that illicit use is more than twice as common as medically based use. 

7 Crucial Caregiving Truths Families Often Overlook

If you clicked to read this story, or someone sent it to you, congratulations: You’re a caregiver.

Moderna and Merck Report Positive Phase 3 Results for Personalized Cancer Therapy

Moderna and Merck have reached a major clinical milestone after their investigational individualized cancer therapy, combined with Merck’s Keytruda, produced positive results in a Phase 3 study involving patients with high-risk melanoma.
- Advertisement -